✦ LIBER ✦

Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial

✍ Scribed by Howard S. Hochster; Michael D. Green; Ronald H. Blum; James C. Wernz; James L. Speyer; Franco M. Muggia

Publisher: Springer US
Year: 1986
Tongue: English
Weight: 258 KB
Volume: 4
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00179596

No coin nor oath required. For personal study only.

✦ Synopsis

Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxydaunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.

📜 SIMILAR VOLUMES

A phase II study of oral idarubicin (4-d

A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer

✍ Nicholas S. A. Stuart; Michael H. Cullen; Terrence J. Priestman; George R. P. Bl 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 352 KB

Idarubicin (4-demethoxydaunorubicin: DMDNR) is an orally active analogue of daunorubicin that has shown promising activity in animal and early clinical studies. We gave idarubicin in a phase II study to patients with advanced breast cancer unresponsive to hormonal manipulation and in some cases to s

Phase I trial of 4-demethoxydaunorubicin

Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses

✍ S. Kaplan; C. Sessa; Y. Willems; M. A. Pacciarini; V. Tamassia; F. Cavalli 📂 Article 📅 1984 🏛 Springer US 🌐 English ⚖ 454 KB

Twenty-four patients with a variety of solid tumors entered a Phase I trial with 4-demethoxydaunorubicin, a new analogue of daunorubicin. The drug was given as a single oral dose of 10-60 mg/m 2 repeated every 3-4 weeks. Leukopenia was the dose-limiting toxicity. Other toxic effects included mild t

A phase II trial of oral 4′ demethoxydau

A phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer

✍ P. Presgrave; R. Woods; R. Kefford; D. Bell; D. Raghavan; J. Levi 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 216 KB

4' Demethoxydaunorubicin, an orally active daunorubicin analogue, was administered to 22 patients with inoperable non small cell lung cancer (NSCLC). Patients were stratified into good and poor risk categories and received doses of 45 mg/m 2 and 40 mg/m 2 respectively at 28 day intervals. All 22 pat

Phase II clinical and pharmacological st

Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer

✍ Robert Milroy; Jeffrey Cummings; Stanley B. Kaye; Stephen W. Banham 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 298 KB

4-Demethoxydaunorubicin (4-DMDNR) is an oral anthracycline with antitumour activity demonstrated in a number of clinical studies. We have assessed the usefulness of 4-DMDNR in 16 patients with advanced small cell lung cancer, none of whom had received previous chemotherapy. There were no complete or

Phase II trial of N-methylformamide in l

Phase II trial of N-methylformamide in lung cancer

✍ Robert L. Cody; Jerome E. Seid; Ronald B. Natale 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 127 KB

Phase II trial of edatrexate in small ce

Phase II trial of edatrexate in small cell lung cancer

✍ Martin Wiesenfeld; James R. Jett; John Q. Su; Theodore A. Braich; Carl G. Kardin 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 2 views